Table 1 Parathyroid hormone-related peptide and parathyroid hormone-related peptide type 1 receptor immunostaining according to clinicopathologic characteristics in 66 patients with advanced laryngeal squamous cell carcinoma
| Â | Â | PTHrP | Â | PTH1R | Â | ||
|---|---|---|---|---|---|---|---|
| Â | N | Negative | Positive | pa | Negative | Positive | p |
Gender: | |||||||
 Male | 61 | 23 (38%) | 38 (62%) |  | 35 (57%) | 26 (43%) |  |
 Female | 5 | 3 (60%) | 2 (40%) | 0.37 | 3 (60%) | 2 (40%) | 1.0 |
Age (years): | |||||||
 < 60 | 26 | 4 (24%) | 13 (76%) |  | 13 (76%) | 4 (24%) |  |
 > 60 | 40 | 22 (45%) | 27 (55%) | 0.15 | 25 (51%) | 24 (49%) | 0.09 |
Site: | |||||||
 Glottic | 47 | 22 (47%) | 25 (53%) |  | 27 (57%) | 20 (43%) |  |
 Transglottic | 19 | 4 (21%) | 15 (79%) | 0.09 | 11 (58%) | 8 (42%) | 1.0 |
Differentiation: | |||||||
Well-Moderately | 32 | 18 (56%) | 14 (44%) | Â | 14 (44%) | 18 (56%) | Â |
 Poorly | 34 | 8 (24%) | 26 (76%) | 0.01 | 24 (71%) | 10 (29%) | 0.04 |
T classification: | |||||||
 T2 | 36 | 13 (36%) | 23 (64%) |  | 20 (56%) | 16 (44%) |  |
 T3-4 | 30 | 13 (43%) | 17 (57%) | 0.62 | 18 (60%) | 12 (40%) | 0.80 |
Stage: | |||||||
 II | 29 | 10 (34%) | 19 (66%) |  | 15 (52%) | 14 (48%) |  |
 III-IV | 37 | 16 (43%) | 21 (57%) | 0.61 | 23 (62%) | 14 (38%) | 0.46 |
Lymph-node: | |||||||
 Negative | 50 | 21 (42%) | 29 (58%) |  | 29 (58%) | 21 (42%) |  |
 Positive | 16 | 5 (31%) | 11 (69%) | 0.56 | 9 (56%) | 7 (44%) | 1.0 |
HER1 | |||||||
 Negative | 24 | 18 (75%) | 6 (25%) |  | 12 (50%) | 12 (50%) |  |
 Positive | 42 | 8 (19%) | 34 (81%) | <0.0001 | 26 (62%) | 16 (38%) | 0.44 |